FDA expands Gardasil 9 approval for head and neck cancer prevention

HPV 9-valent vaccine, recombinant (Gardasil 9, Merck) is approved for use by females aged 9 to 45 years for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58; and genital warts caused by HPV types 6 and 11.

 

Source: Healio